Supporting Critical Go/No-Go Decisions
Our track record in predictive PK/PD modelling in clinical development can support your study design and dose selection and increase translational insights gained from your clinical studies.
Early and late phase studies are within our scope and our team can perform both non-compartmental analyses and population PK/PD analyses across a broad array of therapeutic areas in clinical development.
We invite you to make use of our experience and ability to leverage published data of existing compounds to gain an optimal understanding of exposure variability and treatment responses. Asking the right questions early on can help you optimize study designs for your subsequent clinical studies and tilt the scales at critical go/no-go decisions.